Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses and counter regulatory T cells (Tregs). Here, we report the efficacy and safe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ragnhild Sørum Falk, Bjornar Gilje, Andrea Gombos, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Beate Boge, Randi R. Mathiesen, Lars Julsrud, Øystein Garred, Hege G. Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2024-01-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/12/1/e007990.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!